Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 3 institutions in 2 countries.
Monica L Brown LobbinsDepartment of Pediatrics, University of Tennessee Health Science Center, 50 N. Dunlap, Rm. 461R, Memphis, TN 38103, USA.
Andrzej T SlominskiDepartment of Dermatology, University of Alabama at Birmingham, 500 22nd Street South, Birmingham, AL 35294, USA.ORCID 0000-0001-8963-3995
Karen A HastyMemphis Veterans Affairs Medical Center, 1030 Jefferson Avenue, Memphis, TN 38104, USA.
Sicheng ZhangDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Avenue, Memphis, TN 38103, USA.ORCID 0000-0003-3798-7550
Duane D MillerDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Avenue, Memphis, TN 38103, USA.ORCID 0000-0002-6093-0985
Wei LiDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Avenue, Memphis, TN 38103, USA.ORCID 0000-0002-9522-4474
Tae-Kang KimDepartment of Dermatology, University of Alabama at Birmingham, 500 22nd Street South, Birmingham, AL 35294, USA.
Zorica JanjetovicDepartment of Dermatology, University of Alabama at Birmingham, 500 22nd Street South, Birmingham, AL 35294, USA.
Robert C TuckeySchool of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Perth 6009, Australia.ORCID 0000-0002-5022-4729
Imara-Safi O ScottDepartment of Medicine, University of Tennessee Health Science Center, 956 Court Avenue, Memphis, TN 38163, USA.
Linda K MyersDepartment of Pediatrics, University of Tennessee Health Science Center, 50 N. Dunlap, Rm. 461R, Memphis, TN 38103, USA.ORCID 0000-0001-5268-1870
Arnold E PostlethwaiteDepartment of Medicine, University of Tennessee Health Science Center, 956 Court Avenue, Memphis, TN 38163, USA.
University of Tennessee Health Science Center · USUniversity of Alabama at Birmingham · USThe University of Western Australia · AU
Funding
Mechanism of action and function of novel secosteroid 20(OH)D3 in the skinR01AR073004 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANDRZEJ T SLOMINSKI · 2018 to 2026
$2.9M
Significance of metabolic activation of lumisterol in the skinR01AR071189 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SLOMINSKI, ANDRZEJ T · 2017 to 2021
$1.6M
Canonical and non-canonical vitamin D activation pathways in systemic lupusR21AI149267 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RAMAN, CHANDER, SLOMINSKI, ANDRZEJ T · 2020 to 2021
$408k
Mechanism of action of 20-hydroxyvitamin D3 in dermal fibroblastsR21AR066505 · NIAMS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI SLOMINSKI, ANDRZEJ T · 2014 to 2015
$355k
Arthritis Foundatioin Biomedical Research GrantBLRD VA I01 BX004293National Institute of Health R21AR066505, R01AR071189, R01AR073004, R21 AI149267NIAID NIH HHS R21 AI149267NIAMS NIH HHS R01 AR071189NIAMS NIH HHS R01 AR073004Scleroderma Foundation R073223552University of Tennessee College of Pharmacy Drug Discovery Center general funddsVA 5IP1BX001607-01 , BX004293, BX004151
6 · The paper itself
Abstract
We previously demonstrated that the non-calcemic pregnacalciferol (pD) analog 17,20S (OH)
Indexed as
Tissue DonorsBone Morphogenetic Protein 7Cell LineCollagen Type I, alpha 1 ChainDermisErgocalciferolsFibroblastsFibrosisHumansMatrix Metalloproteinase 1Nuclear ProteinsPlasminogen Activator Inhibitor 1Prostaglandin-E SynthasesRNA, MessengerScleroderma, SystemicTissue Inhibitor of Metalloproteinase-1BMP7 protein, humanBone Morphogenetic Protein 7COL1A1 protein, humanCollagen Type I, alpha 1 ChainErgocalciferolsGLI2 protein, humanMatrix Metalloproteinase 1MMP1 protein, humanNuclear ProteinsPlasminogen Activator Inhibitor 1Prostaglandin-E SynthasesPTGES protein, humanRNA, MessengerTissue Inhibitor of Metalloproteinase-1Zinc Finger Protein Gli2collagenfibrosissclerodermaTGF-β1vitamin D
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Modulation by 17,20S(OH) · full record | OpenQuestion